International, multicentre: Perhexiline in Aortic Stenosis study.

Phase 4

Active, not recruiting

• Conditions: Sever aortic stenosis.; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12606000004561
• Lead Sponsor: The Queen Elizabeth Hospital,Cardiology Department

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-01-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

AVA of < 0.1cm sq. Symptoms of angina and/or exertional shortness of breath.

Exclusion Criteria

No exclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Symptomatic status. It is anticipated that there will be an improvement in symptomatic status after 8 weeks of therapy.[After 8 weeks of treatment]

Secondary Outcome Measures

Name	Time	Method
Functional class, LV function, 6 min walk distance, quality of life as assessed via SF36 and Minnesota Living with Heart Failure questionnaires, BNP concentration.[After 8 weeks of therapy. ];Symptomatic status over long term treatment, correlations between perhexiline level and symptomatic improvement and long term effects.[After 52 weeks of therapy.]